This mechanistic insight provides a theoretical foundation for combination therapy, suggesting that the dual blockade of PD‐1 and CD38 may synergistically enhance immune cell function through multiple pathways, thereby improving therapeutic efficacy in glioma [59]. The gene discussed is CD38; the disease is central nervous system cancer.